TABLE 2.
Proportion of treatment effect on A/H3N2 influenza illness occurrence explained by assays
| Case definitiona (n) | Proportion of treatment effect explained by assay |
||||
|---|---|---|---|---|---|
| HAI, vaccine virus (n = 5,752) | HAI, circulating virus (n = 673) | NT, vaccine virus (n = 675) | NT, circulating virus (n = 675) | N2 ELLA (n = 675) | |
| Laboratory-confirmed influenza associated with RI (n = 152/123) | 0.82 | 0.97 | 0.85 | 1.32 | 0.58 |
| Laboratory-confirmed influenza associated with PD-ILI (n = 121/98) | 0.95 | 1.13 | 1.12 | 1.81 | 0.75 |
| Laboratory-confirmed influenza associated with CDC-ILI (n = 52/48) | 0.86 | 0.65 | 0.75 | 0.99 | 0.51 |
| Antigenically similar influenza associated with RI (n = 37/34) | 0.48 | 0.47 | 0.32 | 0.49 | 0.53 |
| Antigenically similar influenza associated with PD-ILI (n = 30/28) | 0.50 | 0.65 | 0.41 | 0.75 | 0.65 |
| Antigenically similar influenza associated with CDC-ILI (n = 18/17) | 0.27 | 0.27 | 0.17 | 0.32 | 0.28 |
a
n indicates the number of cases. The first number is for the HAI vaccine virus assay, the second is for the other assays.